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Abstract  27 
Myelin destruction is followed by resident glia activation and mobilization of endogenous 28 
progenitors (OPC) which participate in myelin repair. Here we show that in response to 29 
demyelination, mature oligodendrocytes (OLG) bordering the lesion express Ndst1, a key 30 
enzyme for heparan sulfates (HS) synthesis. Ndst1+ OLG form a belt that demarcates 31 
lesioned from intact white matter. Mice with selective inactivation of Ndst1 in the OLG 32 
lineage display increased lesion size, sustained microglia and OPC reactivity. HS production 33 
around the lesion allows Sonic hedgehog (Shh) binding and favors the local enrichment of 34 
this morphogen involved in myelin regeneration. In MS patients, Ndst1 is also found 35 
overexpressed in oligodendroglia and the number of Ndst1-expressing oligodendroglia is 36 
inversely correlated with lesion size and positively correlated with remyelination potential. 37 
Our study suggests that mature OLG surrounding demyelinated lesions are not passive 38 
witnesses but contribute to protection and regeneration by producing HS. 39 
  40 
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INTRODUCTION 41 
In multiple sclerosis (MS), OLG are the target of inflammatory and immune attacks 42 
and their death results in multiple focal demyelinated lesions in the CNS. Myelin loss remains 43 
in defined areas, rather than expanding to involve all of the white matter, and the mechanism 44 
by which demyelinated lesions stop expanding is not understood. Some of these lesions may 45 
stop expanding as inflammation is controlled and lesions are remyelinated. Remyelination 46 
involves OPC recruitment to the lesion, differentiation into myelin forming cells and 47 
remyelination of denuded axons, and the success of this depends on environmental context, 48 
including secreted factors from neighboring cells [1, 2]. This repair process, which occurs 49 
spontaneously in MS patients, is highly variable between patients and between lesions [2]. 50 
Regenerative failure is mainly attributed to defects in OPC recruitment towards the 51 
demyelinated areas [3] and/or to their incapacity to differentiate into myelinating OLG at the 52 
lesion site [1, 4-6].  53 
Multiple factors are involved in this regenerative process including those produced by 54 
reactive astrocytes or microglia and macrophages [7]. These contribute to myelin destruction, 55 
but also to myelin debris removal and beneficial effects by secreting factors that directly or 56 
indirectly support remyelination [8-13]. Interestingly oligodendrocyte lineage cells also 57 
produce factors that modulate remyelination, such as the morphogen shh which is produced 58 
by OLG and OPC at the onset of demyelination in lysophosphatidyl choline (LPC)-induced 59 
lesions [14]. In this context, blocking Shh activity induces an increase in lesion size and a 60 
block in OPC proliferation and differentiation, and conversely Shh overexpression leads to the 61 
attenuation of the lesion extent and promotes oligodendrogenesis [14]. Identifying such actors 62 
involved in myelin damage and remyelination is needed for the design of future protective 63 
and regenerative therapies. 64 
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The presence of a multitude of signals regulating specific steps of remyelination raises 65 
the hypothesis that key factors may be necessary to integrate all these cues. One of these key 66 
factors may be HS proteoglycans (HSPG), as there is now compelling evidence that HSPGs 67 
play a critical role in regulating spatiotemporal coordination of signals in the extracellular 68 
microenvironment of many tissues during brain development and in adulthood [15]. HS 69 
chains consist of linear repeated disaccharide units of N-acetyl glucosamine and glucuronic 70 
acid which are synthesized on proteoglycan core proteins. Ndst enzymes perform the first step 71 
of these sugar modifications thus specifying the functional properties of HSPGs [16-18]. 72 
Among the four known Ndst enzymes, Ndst1 appears as the key enzyme for addition of N-73 
sulfated motifs to HS chains in brain during development, as shown by limited functional 74 
redundancy mediated by other Ndst enzymes (2-4) in Ndst1 KO mice [19, 20]. During 75 
development, HS proteoglycans provide an important signaling scaffold allowing spatial 76 
concentration or trapping of numerous molecules such as morphogens and growth factors [21] 77 
and the control of receptor activity [21-24]. Following CNS injury, HSPGs are known to play 78 
a pivotal role in post-lesional plasticity and regeneration [25] [26]. Some HS proteoglycans 79 
are over-expressed by reactive astrocytes in injured mouse brain and provide positive [25] or 80 
negative [26] environmental support for axon regenerative responses. In vitro, HS 81 
proteoglycans can prevent OLG differentiation, maintaining OPC in an immature proliferative 82 
phenotype by acting as a FGF-2 co-receptor [27, 28]. Therefore, we hypothesized that HS 83 
proteoglycans play an organizing role in controlling myelin damage and repair.  84 
Here we show that mature OLG bordering a demyelinated lesion limit lesion extension 85 
and influence OPC mobilization via HS production. Using a model of acute focal 86 
demyelination of the corpus callosum in mice, we show that Ndst1 expression is induced in 87 
OLG around the lesion throughout the phases of demyelination and remyelination. Ndst1 88 
expression and subsequent HS accumulation mostly accumulate at the margin of the lesion, 89 
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delimiting the lesion from the intact corpus callosum during demyelination. To evaluate the 90 
relevance of Ndst1 induction for lesion formation and repair, we exposed genetically modified 91 
mice with selective deletion of Ndst1 in oligodendroglia to focal demyelination of the corpus 92 
callosum. Lack of Ndst1 in OLG resulted in an increased lesion size, and a sustained OPC and 93 
microglia/macrophage activation at the early stage of remyelination. HS enrichment correlates 94 
with and is necessary for the binding around the lesion site of the morphogen Shh, suggesting 95 
that Ndst1 expression and HS secretion by OLG enhances Shh signaling after demyelination, 96 
thus favoring remyelination [14, 29].  Furthermore, NDST1 expression in OLG was also 97 
increased in human postmortem tissues from multiple sclerosis patients. This increased 98 
density of NDST1+ OLG in lesions was inversely correlated with the size of the lesion and 99 
positively correlated with remyelination. 100 
 101 
RESULTS 102 
Demyelination triggers Ndst1 up-regulation by OLG and creates a transient N-103 
sulfated belt around the lesion 104 
To identify candidates that could regulate interactions between progenitors and the injured 105 
environment, a microarray analysis was performed to compare gene expression in purified 106 
oligodendroglia from adult healthy and demyelinated animals [30]. One of the most robustly 107 
and significantly up-regulated genes after demyelination was Ndst1, a key enzyme of HS 108 
proteoglycan synthesis (fold increase of 48.9 and 14.0 in two different trials; p≤0.001; 109 
microarray data are available at GEO with accession number GSE47486). This up-regulation 110 
of Ndst1 was confirmed in vivo at 21 days in mice exposed to EAE by in situ hybridization 111 
combined with Olig2 labeling, a pan OLG marker. While Ndst1 was not detected in the 112 
corpus callosum of control brains (Figure 1-figure supplement 1A), it was highly expressed 113 
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by the Olig2+ population after EAE in the corpus callosum (Figure 1-figure supplement 1B-114 
C) in close proximity to lesion sites (Figure 1-figure supplement 1C). 115 
To characterize the up-regulation of Ndst1 after demyelination, we used LPC to trigger focal 116 
demyelination lesions in the mouse corpus callosum (Figure 1A). In this model, 117 
demyelination is not T cell driven, and demyelination and remyelination proceed in a 118 
stereotypic sequence: demyelination occurs within few days, endogenous progenitor 119 
mobilization peaks at 8 dpi and is followed by OPC differentiation [8]. Production of new 120 
myelin is then observed after 2 weeks. Demyelination of the corpus callosum is clearly visible 121 
after LPC injection in a reporter mouse where myelin fluoresces green (plp-GFP) [31, 32] by 122 
the total loss of GFP signal around the injection site (Figure 1-figure supplement 2). The 123 
lesion is also characterized by a strong increase in cell density (due to glia proliferation and to 124 
microglia/macrophage infiltration) observed by Hoechst staining (Figure 1-figure supplement 125 
2) that strictly coincides with loss of GFP fluorescence.  126 
We first evaluated Ndst1 expression levels by performing RT-qPCR analysis using the corpus 127 
callosum of healthy or demyelinated mice on the ipsi- and contralateral sides to the LPC 128 
injection, 8 days post injection (dpi). We quantified a mean 41% increase in the Ndst1 129 
expression level in the demyelinated corpus callosum compared to healthy corpus callosum 130 
(Figure 1B; p=0.05). Ndst1 transcripts were found up-regulated in demyelinated corpus 131 
callosum by in situ hybridization at 5 dpi during demyelination (Figure 1C-F), 8 dpi (Figure 132 
1G), and 14 dpi (Figure 1H). At days 5 and 8 dpi, Ndst1 expressing cells delimited a belt 133 
around the lesion site. Weak staining was observed distal to the lesion, in the contralateral 134 
side of the corpus callosum and at the core of the lesion (Figure 1C-D). Thus, the induction of 135 
demyelination in the corpus callosum triggers Ndst1 up-regulation, and this change is 136 
sustained throughout the phases of demyelination and remyelination. 137 
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Since Ndst1 catalyzes a mandatory step in the synthesis of HS chains, its expression is 138 
likely to reflect the distribution of HS. We thus examined the outcome of Ndst1 activity by 139 
analyzing the distribution of N-sulfated motifs after demyelination. To do so, we used the 140 
anti-HS antibody 10E4 [19, 33], which exclusively detects the N-sulfated motifs produced by 141 
Ndst1 activity [20]. While no staining was detected in the contralateral corpus callosum 142 
(Figure 2A), N-sulfated HS positive puncta formed a belt around the demyelination lesion 143 
(Figure 2B-C), similar to the profile of Ndst1-induction. Furthermore, as with Ndst1 144 
expression, no HS staining was detected within the lesion (Figure 2B-C). This staining is 145 
specific as it was absent after treatment with Heparinase, an enzyme that digests N-sulfated 146 
motifs on the HS chains [34] (Figure 2D). This correlation between Ndst1 up-regulation and 147 
the presence of a highly N-sulfated microenvironment indicates the functional activity of 148 
Ndst1 after LPC-induced demyelination in the corpus callosum. 149 
The phenotype of Ndst1 expressing cells around the demyelinated lesion was 150 
examined at 5 dpi, using co-staining for several markers combined with Ndst1 in situ 151 
hybridization. We found that Ndst1 expressing cells are immunopositive for Olig2 (Figure 152 
3A) and Plp+ using double in situ hybridization (Figure 3B). We quantified that 98.0±1.5% 153 
Ndst1+ cells express Olig2 indicating that virtually all Nsdt1 cells belong to the 154 
oligodendroglia lineage. We found that Ndst1 expressing cells are immunopositive for Olig2, 155 
PDGFRα and CC1 (Figure 3A,C,D) and Plp+ using double in situ hybridization (Figure 3B) 156 
At 5 dpi, 97.5±1.7% of Ndst1 expressing cells were co-labelled with CC1, a mature OLG 157 
marker (Figure 3D), while only 0.8±0.3% co-expressed the OPC marker PDGFRα (Figure 158 
3C).  159 
Of note, in the belt delimitated by Ndst1 staining surrounding the lesion, only half of 160 
the Olig2+ cells expressed Ndst1 (45.8±3.4%). This may indicate that not all stages of 161 
oligodendroglial maturation or not all oligodendrocytes respond equally to the lesion. We 162 
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observed that, 8.5±3.2% of PDGFRα+ cells and 48.9±8.5% of CC1+ cells surrounding the 163 
lesion co-labelled with Ndst1. Our data indicate that the majority of Ndst1+ cells around the 164 
lesion are mature OLG which are more prone than OPC to activate Ndst1 expression in 165 
response to demyelination 166 
 167 
Deletion of Ndst1 in the Olig2+ population transiently worsens the extent of 168 
demyelination and modifies OPC reactivity after LPC injection.  169 
 170 
To test if Ndst1 activity in oligodendroglia controls demyelination and/or remyelination, we 171 
generated transgenic mice with a conditional deletion of Ndst1 in Olig2+ cells, by breeding 172 
Olig2-Cre+/- mice and Ndst1 
Flox/Flox
 mice [19, 35]. The efficiency of inactivation of Ndst1 173 
expression in Olig2 cells was monitored by in situ hybridization in the context of LPC-174 
induced demyelinating lesion, revealing a drastic decrease in Ndst1 expression in lesioned 175 
mutants compared to control (Figure 4-figure supplement 1A-D). As revealed by 176 
immunostaining using the anti-HS antibody, a strong reduction in N-sulfated HS positive 177 
puncta around the demyelination lesion was also observed in mutant compared to control 178 
(Figure 4-figure supplement 1G-H). In healthy mice, quantitative analysis of myelin content 179 
(Figure 4-figure supplement 2A-C; p=0.2), astrocyte density (Figure 4-figure supplement 2D-180 
F; p=0.4) and oligodendroglial lineage cell density (Figure 4-figure supplement 2G-L; p=0.6, 181 
0.2 and 0.2 for Olig2, CC1 and PDGFR cell density respectively) revealed no difference 182 
between control (Olig2-Cre+/-) and mutant (Olig2-Cre+/-; Ndst1 
Flox/Flox
) adult mice, thus 183 
indicating that conditional deletion of Ndst1 in the Olig2+ cell population does not interfere 184 
with brain development and with subsequent myelin maturation. 185 
We first performed LPC-induced demyelination of the corpus callosum in control and 186 
mutant mice and measured the size of the lesion at 4, 8 and 14 dpi. As before, lesions were 187 
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identified based on the high density of nuclei at the injection point (Figure 1-figure 188 
supplement 2).  While no difference was detected at 4 dpi (0.226±0.036 vs. 0.159±0.033 mm³ 189 
in control and mutant mice, respectively; p=0.23), a significant two-fold increase in lesion 190 
size was observed in mutant compared to control mice at 8 dpi (0.199±0.032 vs. 0.097±0.022 191 
mm³, p=0.023) (Figure 4A-C). During the remyelination phase (between 8 and 14 dpi), the 192 
lesion area decreased in both groups reaching comparable sizes at 14 dpi (0.033±0.02 vs. 193 
0.028±0.012 mm³ in control and mutant mice, respectively; p=0.97) (Figure 4C).  194 
We examined how these changes in the local environment in these mutant mice affect 195 
OPC mobilization during remyelination by analyzing Olig2+ cells density (Figure 4D-F), 196 
maturation status (Figure 4G-I) and proliferation (Figure 4J-O). In accordance with 197 
demyelination, there was a marked decrease in Olig2+ cell density within the demyelinated 198 
area compared to healthy corpus callosum in both groups at 4 dpi (55.5±3.3% and 57.3± 3.9% 199 
decrease in control and mutant mice respectively, p=0.03 and p=0.001) (Figure 4F), reflecting 200 
the loss of oligodendrocytes. We observe that in both conditions the density of Olig2+ cells 201 
returned to uninjected control values at 14 dpi. Quantification of mean cell densities of mature 202 
OLG (CC1+) (Figure 4G-I) within the lesion throughout the time course revealed no 203 
significant difference between the two groups indicating that cell differentiation is not 204 
affected by Ndst1 inactivation. 205 
We observed that the percentage of Ki67+ proliferating cells within the lesion area 206 
was two-fold increased in Ndst1 mutant
 
mice compared to control mice at 8 dpi (217.8±42.8% 207 
vs. 100±13.5% in mutant and control mice, respectively, p=0.037) (Figure 4J-K). Some of 208 
these proliferative cells are OPC since they co-express Olig2 and Ki67 (Figure 4M-O). At 4 209 
dpi, the percentage of proliferating Olig2+ cells was lower (but not significantly different) in 210 
mutant mice compared to control (23±3.6% vs. 17±2.6% of Ki67+/Olig2+ cells in control and 211 
mutant mice, respectively, p=0.29) (Figure 4O).  At 8 dpi, the percentage of proliferating 212 
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Olig2+ cells was significantly increased in mutant mice (7.6±0.8% vs 3.2±0.5% in mutant and 213 
control mice, respectively, p=0.0004) indicating a prolongation of OPC reactivity during the 214 
repair phase. These data show that OPC reactivity is altered in absence of Ndst1 at the onset 215 
of remyelination (8dpi). To note, no significant difference in cell death was detectable in the 216 
lesion between the two groups at 4 dpi (341.7±4.5 and 357±111.1 caspase3+ cells per mm² in 217 
control and mutant mice, respectively, p=0.28). 218 
Together, these results suggest that Ndst1 expression in the Olig2+ population has no 219 
effect on initial demyelination (equivalent lesion size at 4 dpi) but protects the lesion from 220 
enlarging and participates in the control of OPC mobilization.  221 
 222 
Deletion of Ndst1 in the Olig2+ population modulates microglia/macrophage activation. 223 
While the total number of proliferating cells within the lesion area was strongly increased in 224 
Ndst1 mutant
 
mice compared to control mice at 8 dpi  (Figure 4J-L), the percentage of OPC 225 
among these cells represent only 7.6% in the mutant. These data suggest that Ndst1 loss in the 226 
Olig2 population indirectly modulates proliferation of surrounding cell types in the context of 227 
a demyelinating lesion. To address this, we evaluated the proliferation and activation states of 228 
the macrophage/microglia participating in demyelination-remyelination in this acute 229 
demyelination model. We found a robust increase in proliferation of CD68+ cells in mutant 230 
compared to control mice at 8 dpi (166.4±24.3 vs. 79.3±20.6 CD68+/Ki67+ cells per mm² in 231 
mutant and control mice, respectively, p=0.026) (Figure 5A-C). Upon CNS insult, 232 
microglia/macrophages are quickly activated, changing their shape from ramified to 233 
rhomboid. Rhomboid versus ramified polarization of total or activated microglia/macrophages 234 
was examined using respectively Iba1 (Figure 5D-E) and CD68 (Figure 5F-H) 235 
immunostaining. We observed a switch of the microglia/macrophage polarization among the 236 
whole Iba1 and CD68 population in favor of the rhomboid phenotype in mutant mice 237 
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compared to control at 8 dpi. This effect was quantified for activated microglia (ratio of 238 
rhomboid /ramified CD68+ cells of 0.28±0.05 in control vs. 0.66±0.1 in mutant mice, 239 
p=0.038) (Figure 5H). While the activation phenotype tended to decrease between 4 and 8 dpi 240 
in control mice, it tended to increase in mutant animals. We then evaluated the expression 241 
level of Cox2, a marker of pro-inflammatory (M1) microglia/macrophage [36] and observed a 242 
significant 77% increase in the number of Cox2+ microglial cells in mutant mice compared to 243 
control (p=0.01), indicating a delay in the pro-inflammatory (M1) to pro-regenerative (M2) 244 
switch in the absence of Ndst1 in oligodendroglia (Figure 5I-K).  These results demonstrate 245 
that Ndst1 deletion in the Olig2 population is sufficient to enhance microglia/macrophage 246 
proliferation and activation at the lesion site at the onset of remyelination. 247 
 248 
Shh binds to HS around the focal LPC-induced demyelinated lesion in the corpus 249 
callosum  250 
As previously mentioned, HSPGs form a scaffold that shapes the distribution and activity of 251 
numerous growth factors and morphogens during development and provide environmental 252 
support for regenerative responses following CNS injury. Among several known HSPG-253 
binding morphogens, Shh was previously identified as a positive regulator for myelin repair 254 
[14, 29]. In order to determine whether lesion-induced HS enrichment around the lesion site 255 
could influence Shh distribution (hence signaling), we used an Alkaline Phosphatase (AP) 256 
tagged version of Shh (AP-SHH) to directly assay its binding capacity in demyelinating 257 
context. Knowing that the CW sequence serves as a major HS-binding site for Shh [37, 38], 258 
we also used AP-SHH recombinant proteins deleted for the CW sequence (AP-SHH-259 
CWdeleted), as a control. Probes were incubated on fresh brain sections obtained 4 days after 260 
LPC injections. AP-Shh binding was observed in the cortex in healthy conditions (data not 261 
shown) and after lesion (Figure 6B,B’). While no AP-Shh binding was observed in healthy or 262 
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uninjured contralateral corpus callosum, AP-Shh binding delimited a clear belt surrounding 263 
the lesion site in the corpus callosum after LPC injection (Figure 6B-B’). In contrast, AP-Shh-264 
CWdeleted did not bind around the same lesion on adjacent sections (Figure 6C-D). As AP-265 
Shh binding depends on the integrity of its HS-binding motif, this indicates that endogenous 266 
Shh localization and concentration may be controlled by HS production by peri-lesional OLG. 267 
In order to assess whether SHH signaling was indeed reduced in Ndst1 mutant
 
mice compared 268 
to control mice, we quantified Ptch1 (the main SHH receptor) expression around LPC-269 
induced demyelination lesions at 8 dpi using RNAscope (Figure 6E-G). Ndst1 mutant mice 270 
exhibited 38% decrease in Ptch1 expression compared to control mice (8.6±0.7 vs 13.8±3.0 271 
dots/cells in mutant and control mice respectively, n=5 mice/group) although it did not quite 272 
reach significance (p=0.07) (Figure 6E). Altogether these results suggest that lack of NDST1 273 
in OLG lineage attenuates SHH signaling following demyelination insult.  274 
 275 
NDST1 is expressed by oligodendroglia in multiple sclerosis lesions and correlates 276 
with lesion size and remyelination 277 
To examine the relevance of our findings for multiple sclerosis (MS) physiopathology, we 278 
examined Ndst1 expression in MS tissue. We first probed the snRNAseq data provided by 279 
Jakel et al work [39], and observed that few cells express Ndst1 in both control and MS 280 
tissues but when the oligodendrocytes that express Ndst1 are compared, there is a trend to 281 
increased expression in MS tissue (Figure 7-figure supplement1). Because such approach 282 
identifies around 15% only of nuclear RNA, we then directly examined the expression pattern 283 
of NDST1 protein in MS patient brain sections. Normal appearing white matter (WM), 284 
remyelinating, active, chronic active or chronic inactive lesions were analyzed. While NDST1 285 
staining was very weak in control WM (without MS), we observed a significant increase of 286 
NDST1 labeling in MS patients WM (Figure 7A-B). Comparison of healthy control, MS 287 
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normal appearing WM and MS lesions showed that there is a significant increase of NDST1 288 
staining in multiple sclerosis lesions vs. control (p=0.0014) (Figure 7C). Comparison of each 289 
MS lesion with its surrounding normal appearing WM using a paired t test, revealed that there 290 
is significantly more NDST1 labeling in MS lesions compared to their surrounding normal 291 
appearing WM (paired two-tailed t test, t9=3.39, p=0.0095). However, NDST1+ cells were 292 
distributed evenly throughout the lesion, rather than forming a delimiting band (Figure 7-293 
figure supplement 2D).  294 
We then performed double-labeling immunohistochemistry to characterize NDST1-positive 295 
cells in various types of lesions and normal appearing WM, using OLIG2 for oligodendroglia 296 
(Figure 7D), GFAP for astrocytes (Figure 7E), NEUN for neurons (Figure 7F) and IBA1 for 297 
microglia/macrophages (Figure 7G). Quantitative analysis showed that the majority of 298 
NDST1 cells were oligodendroglia in all types of lesions (remyelinated, active, chronic active, 299 
chronic inactive) and in normal appearing WM (Figure 7H). 300 
The vast majority of OLIG2+ cells in the lesions expressed NDST1, with a gradual reduction 301 
in the proportion of OLIG2+NDST1+ cells as lesions become more chronic, and with 302 
significantly fewer in control tissue (Figure 7I; p=0.016). The number of NDST1+ 303 
oligodendroglia in each lesion was inversely correlated with the lesion’s size (Figure 7J). As 304 
blocks of MS tissue contained multiple lesions and sometimes we had multiple blocks from 305 
the same patient (see Table1), we gave each patient an overall remyelination ability score 306 
corresponding to how many lesions in the blocks from that patient were remyelinated, or 307 
likely to remyelinate if the patient had survived. Here, we were aiming to see whether patients 308 
considered being “good remyelinators” using this score express more NDST1. A lesion was 309 
given a score of 3 points (complete remyelination), 2 points (active - likely to remyelinate), 1 310 
point (chronic active less likely to remyelinate) and 0 points (chronic inactive -unlikely to 311 
remyelinate). The total score of all the lesions per patient was then divided by the number of 312 
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lesions per patient, to allow comparisons. We showed that NDST1+ cell density positively 313 
correlated with patient’s score of remyelination ability (Figure 7K). These data reveal that MS 314 
tissues with a higher repair potential (containing most active and remyelinated lesions) 315 
display a high number of NDST1+ cells therefore suggesting that higher numbers of NDST1+ 316 
cells in a lesion may provide a positive environmental support for myelin repair. 317 
 318 
 319 
 320 
 321 
322 
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DISCUSSION 323 
In this study, we investigated the role of Ndst1 and HS after demyelination. Using LPC-324 
induced demyelination of the corpus callosum in mouse, we showed for the first time that 325 
Ndst1-dependent N-sulfate sugar modifications occur at the onset of demyelination and 326 
during remyelination. These modifications limit the extension of demyelination and create a 327 
permissive substrate enhancing remyelination. First, we show that Ndst1 is almost exclusively 328 
expressed by oligodendroglia present at the margin of the lesion delimiting the lesion from the 329 
intact corpus callosum. Second, we found that the conditional deletion of Ndst1 in the Olig2 330 
population concomitantly triggers an enlargement of the LPC-induced demyelinated area, 331 
alters OPC mobilization and favors the pro-inflammatory (M1) phenotype in microglia. We 332 
propose that these effects could be mediated through HS dependent binding of the morphogen 333 
Shh which has been shown to be a positive regulator of myelin repair through increased 334 
oligodendrogenesis and microglial regulation [14, 29]. Finally, using MS brain tissue 335 
samples, we show that NDST1 is up-regulated, especially within lesions and that the density 336 
of NDST1+ cells in these lesions is negatively correlated to lesion size, and positively 337 
correlated to the patient’s potential remyelination ability. Our data suggest that Ndst1/HS 338 
expressed by oligodendrocytes around the lesion create a protective and permissive 339 
environment playing a positive role in myelin repair. 340 
 341 
HS and chondroitin sulfates are the two main classes of sulfated proteoglycans constituting 342 
the extracellular space. Chondroitin sulfates are strongly expressed by astrocytes and 343 
microglia providing a hostile environment impeding regeneration and remyelination following 344 
brain injury [40-43]. Enzymatic degradation of chondroitin sulfate proteoglycans using 345 
chondroïtinase ABC treatment in vivo promotes OPC mobilization and remyelination [43]. In 346 
vitro, chondroitin sulfates reduce OPC maturation [44] and in vivo the use of a CSPG 347 
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synthesis inhibitor promotes OPC maturation and accelerates remyelination following focal 348 
demyelination in mice [45]. A recent study has shown that Surfen, a proteoglycan binding 349 
agent, reduces inflammation and delays remyelination. [46]. Our study provides evidence for 350 
a beneficial effect of HS proteoglycans (and upstream enzyme Ndst1) on limiting 351 
demyelinated lesion size and promoting remyelination. Here we propose that HS on mature 352 
OLG changes the amount/stability of soluble factors, and thus the recruitment and 353 
proliferation of surrounding cells (such as OPC or microglia). Thus, OLG modify their 354 
environment which in turn regulates the behavior of cells in the lesioned CC including 355 
microglia and OPC. Therefore, two classes of sulfated proteoglycans have opposite effects on 356 
myelin repair; one being detrimental (chondroitin sulfates), and the other (HS) having a 357 
beneficial effect. Interestingly, both are found at the margin of the lesion, but while the 358 
chondroitin sulfates are secreted by astrocytes and microglia, HS are expressed by 359 
oligodendroglia. Our data show that the majority of Ndst1+ cells at the margin of the LPC-360 
induced lesion are mature CC1+ OLG revealing that mature OLG around a demyelination 361 
lesion, respond to post lesional cues. Interesting, recent data have shown that pre-existing 362 
mature OLG can also participate to myelin regeneration in human and rodent by forming new 363 
myelin sheaths further indicating that mature OLG have an active role in myelin repair [47, 364 
48].  365 
 366 
This OLG response to nearby demyelination appears propitious to regeneration by restricting 367 
the lesion spread, favoring OPC mobilization and modulating microglia response.  368 
Macrophages/microglia participate to myelin repair through myelin debris clearance and the 369 
secretion of regenerative factors that altogether promote the recruitment of OPC, their 370 
proliferation and differentiation into mature myelin-forming cells. Activated microglia also 371 
produces various pro-inflammatory mediators (cytokines, chemokines…) that may affect 372 
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OPC since they express a battery of receptors [49]. Recent studies have shown that efficient 373 
remyelination required the dynamic regulation of functional microglia phenotype [7, 50]. 374 
Microglia respond to demyelination with initial pro-inflammatory phenotype (M1) followed 375 
later by pro-regenerative phenotype (M2) which actively contributes to myelin repair [7, 51]. 376 
Interestingly, this transition from pro-inflammatory to pro-regenerative phenotype is a rate-377 
limiting step in the repair process since intra-lesional depletion of pro-regenerative microglia 378 
blocks oligodendrocyte differentiation and delays the regenerative process [7]. In our study, 379 
lack of Ndst1/HS from Olig2+ cells in transgenic mice leads to increased microglial 380 
proliferation, a strongly activated rhomboid polarization of CD68-expressing cells and an 381 
increased density of pro-inflammatory (M1) microglia at an early stage of the remyelination 382 
phase (8 dpi). Altogether these effects may contribute to enlargement of the demyelinated 383 
lesion and delayed myelin repair. This non-cell autonomous effect observed on microglia 384 
activation could in turn disturb OPC mobilization and thus modify the repair process [7].  385 
 386 
The beneficial action of HS may be related to their ability to bind numerous growth factors 387 
and morphogens, as observed during development [23]. HS can act as co-receptors for these 388 
ligands or are involved in the stabilization and/or local concentration of ligands in the 389 
extracellular space, which modulates cell signaling. Ndst1 global knock out mice display 390 
developmental defects that mainly resemble those found in embryos deficient for Shh or FGFs 391 
[52]. FGF and Shh implication in myelin regeneration and glial reactivation have been 392 
extensively examined in mouse models of demyelination (for review, see [8]). A role of both 393 
factors in remyelination was first inferred by correlating their spatial and temporal 394 
upregulation after demyelination particularly in LPC-induced demyelination [14, 53-55] 395 
Concerning FGF, conflicting results have been published on its activity [56-61]. A recent 396 
report has addressed this issue using the simultaneous ablation of both FGFR1 and FGFR2 397 
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specifically in cells from the oligodendrocyte lineage [62]. This study revealed that FGF 398 
signaling is not required for myelin regeneration in acute models of demyelination including 399 
LPC-induced demyelination of the spinal cord and cuprizone intoxication [62].  Overall, in all 400 
these analyses the phenotypes observed after LPC-induced demyelination never recapitulate 401 
(even partially) the phenotype observed in the present report using Olig2-Cre; Ndst1 
Flox/Flox
 402 
mice. This suggests that FGF is probably not the main ligand regulated by HS activity during 403 
myelin repair in this model.  404 
By contrast, blocking Shh activity leads to an increase in demyelinated lesion size and an 405 
altered OPC mobilization after LPC-induced demyelination [14] similar to what we observe 406 
in Olig2-Cre; Ndst1 
Flox/Flox
 mice. However, these effects persist at later time points at the end 407 
of remyelination, and OPC maturation is also inhibited after Shh inactivation [14]. Of note, 408 
recent in vitro findings show that the proteolytic processing of Shh required for signaling 409 
pathway activation [63] is finely regulated by HS chains [64], perhaps influencing Shh 410 
concentration and/or spreading. Here we show that Shh binds to HS around demyelinated 411 
lesions in mouse. Thus, we propose that HS removal may delay the local accumulation around 412 
the demyelinated lesion of Shh produced by OLG [14] and/or delay Shh activation and 413 
spreading, leading to a reduction in signaling as suggested by reduced Ptch1 expression at 414 
early time-points. Later, the sustained production of Shh may overtake the absence of HS, 415 
leading to efficient recovery. Interestingly, Ferent et al. have shown that the main Shh 416 
responding cells (cells expressing Gli1 and/or Smo) after LPC-induced demyelination of the 417 
corpus callosum are OLG and microglia [14]. These observations further support the idea that 418 
sustained microglia and OPC activation in the absence of HS are at least in part due to altered 419 
Shh signaling.  420 
Finally, we can confirm that NDST1 is also over-expressed in human MS brain samples, 421 
mostly in Olig2-positive oligodendroglia. High levels of HS proteoglycans and chondroitin 422 
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sulfate proteoglycans have been previously associated with inflammatory CNS diseases such 423 
as MS [65-68]. Here, we show that NDST1 is upregulated within and surrounding MS lesions 424 
in post mortem tissue compared to control. NDST1 expression is significantly higher in MS 425 
lesions compared to surrounding normal appearing white matter (NAWM), irrespective of 426 
lesion type (remyelinated, active, chronic active or chronic inactive). The distribution of the 427 
NDST+ cells was different from the mouse model, in that we saw no surrounding band of 428 
positive cells, but instead the entire lesions contained positive cells, though the majority of 429 
these cells were OLIG2+ oligodendroglia. This difference may be related to the timing of 430 
examination of the tissue after the lesion onset, which is later in the human tissue, and 431 
secondary to poorer repair in humans. In MS lesions, a large proportion of these OLIG2+ 432 
cells express NDST1, suggesting that at least some of these are mature, but we were unable to 433 
distinguish mature and immature oligodendroglia in this tissue (due to limitations in double-434 
labelling using effective antibodies in human tissues). However, these observations still 435 
concur with our mouse data indicating that oligodendroglia respond to neighboring 436 
demyelination. Also consistent with our results showing increased lesion size in Olig2-Cre+/-437 
; Ndst1 
Flox/Flox
 mice, in human samples we observed an inverse correlation between lesion 438 
size and density of NDST1-expressing Olig2+ cells. NDST1 cell density also positively 439 
correlates with a pathological score of potential remyelination ability in patients. 440 
Overall, our results in mouse and human tissues suggest that NDST1/HS levels are an 441 
indicator of oligodendroglial reactivity after demyelination, and are involved in both limiting 442 
the size of the lesion and creating a permissive environment for myelin regeneration. 443 
Furthermore, this study shows for the first time that mature oligodendrocytes around lesion 444 
are active players during demyelination/remyelination by producing HS and thus modifying 445 
the local environment. This study will help improve understanding the neuropathology of MS 446 
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in both limitation of damage and promotion of remyelination, which may in the future help 447 
target pharmacological approaches to potentiate myelin repair. 448 
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MATERIALS AND METHODS 454 
 455 
Key Resources Table 
Reagent 
type 
(species) or 
resource 
Designation 
Source or 
reference 
Identifiers 
Additional 
information 
Genetic 
reagent 
(M.musculus) 
Olig2Cre 
PMID:18046410 
 
  
B6D2F1J/Rj 
genetic 
background 
Genetic 
reagent 
(M.musculus) 
Ndst1flox/flox PMID:16020517  
Dr. Kay Grobe 
(University of 
Münster, 
Münster, 
Germany) 
Genetic 
reagent 
(M.musculus) 
Plpgfp 
PMID:15906234 
PMID:11756747 
 
Dr. Bernard 
Zalc 
(University of 
Sorbonne, 
Paris, France) 
Biological 
sample (H. 
Sapiens) 
Brain tissue from 
9 MS patients 
UK Multiple 
Sclerosis Tissue 
Bank 
(MREC/02/2/39) 
 
Postmortem 
unfixed frozen 
Biological 
sample (H. 
Brain tissue from 
4 Control 
UK Multiple 
Sclerosis Tissue 
 
Postmortem 
unfixed frozen 
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Sapiens) patients Bank 
(MREC/02/2/39) 
Cell line (H. 
Sapiens) 
293T HEK ATCC CRL3216    
Transfected 
construct 
(M.musculus) 
pWiz-AP-SHH PMID: 16020517   
Production of 
AP-tagged 
SHH 
recombinant 
protein 
Transfected 
construct 
(M.musculus) 
pWiz-AP-SHH-
CWdeleted 
PMID: 11959830   
Production of 
AP-tagged 
deleted SHH 
recombinant 
protein 
Antibody 
Rabbit 
polyclonal 
anti-OLIG2 
Millipore AB9610  IF (1/1000) 
Antibody 
Rabbit 
polyclonal 
anti-OLIG2 
Sigma-Aldrich HPA003254 IF (1/100) 
Antibody 
Mouse 
monoclonal 
anti-APC (clone 
CC1) 
Calbiochem OP-80 IF (1/400) 
Antibody 
Rat monoclonal 
anti-PDGFRa 
(clone APA5) 
Millipore CBL1366 IF (1/250) 
Antibody 
Mouse 
monoclonal anti-
MBP 
Millipore MAB384 IF (1/500) 
Antibody 
Mouse 
monoclonal anti-
Ki67 
BD Pharmingen 556003 IF (1/500) 
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Antibody 
Rabbit 
polyclonal anti-
Caspase 3 
Cell Signalling 9661 IF (1/200) 
Antibody 
Rabbit 
polyclonal anti-
GFAP 
Dako Z0334 IF (1/400) 
Antibody 
Goat polyclonal 
anti-IBA1 
Abcam Ab5076 IF (1/500) 
Antibody 
Rabbit 
polyclonal anti-
IBA1 
Wako Chemicals 019-19741 IF (1/500) 
Antibody 
Rat monoclonal 
Anti-CD68 
Abcam Ab53444 IF (1/400) 
Antibody 
Rabbit 
polyclonal anti-
COX2 
Abcam Ab15191 IF (1/400) 
Antibody 
Mouse 
monoclonal IgM 
anti-N-sulfated 
motifs on HS 
chains 
(clone10E4) 
Amsbio 370255-1 IF (1/500) 
Antibody 
Mouse 
monoclonal anti-
NDST1 
Abcam ab55296 IF (1/50) 
Antibody 
Rabbit 
polyclonal anti-
NeuN 
Abcam Ab104225 IF (1/500) 
Sequence-
based 
reagent 
 Ndst1_F 
Eurofins 
Genomics 
RT-qPCR 
primers 
gctggacaagatc
atcaatgg 
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Sequence-
based 
reagent 
 Ndst1_R 
Eurofins 
Genomics 
RT-qPCR 
primers 
acacagtacttcta
cgactatcc 
Sequence-
based 
reagent 
 Gapdh_F 
Eurofins 
Genomics 
RT-qPCR 
primers 
gggttcctataaata
cggactgc 
Sequence-
based 
reagent 
Gapdh_R 
Eurofins 
Genomics 
RT-qPCR 
primers 
ctggcactgcaca
agaagat 
Sequence-
based 
reagent 
plp/dm20 
PMID:9373029 
 
 Probe for ISH 
Sequence-
based 
reagent 
Ndst1 PMID:16020517  Probe for ISH 
Sequence-
based 
reagent 
Ptch1 
Advanced Cell 
Diagnostics 
402811-C2 
Probe for 
RNAScope 
Peptide, 
Recombinant 
Protein 
Human NDST1 Abcam ab116875    
Commercial 
assay or kit 
RNAscope 
Multiplex 
Fluorescent kit 
Advanced Cell 
Diagnostics 
323133   
Commercial 
assay or kit 
DAB Peroxidase 
(HRP) Substrate 
Kit (with Nickel) 
Vector 
Laboratories 
SK-4100  
Commercial 
assay or kit 
VECTOR Blue 
AP Substrate Kit 
Vector 
Laboratories 
SK-5300  
Commercial 
assay or kit 
ImmPRESS™-
AP Anti-Rabbit 
IgG Polymer 
Detection Kit 
Vector 
Laboratories 
MP-5401  
 24 
Commercial 
assay or kit 
ImmPRESS™ 
HRP Anti-Mouse 
IgG Polymer 
Detection Kit 
Vector 
Laboratories 
MP-7402  
Chemical 
compound, 
drug 
Lysolecithin 
Sigma-Aldrich-
Merck 
L1381 
 
Chemical 
compound, 
drug 
Heparinase  Amsbio 100700  
Chemical 
compound, 
drug 
Lipofectamine 
2000 
Invitrogen 11668-030  
Chemical 
compound, 
drug 
Vector Bloxall 
Vector 
Laboratories 
SP-6000  
Software, 
algorithm 
ImageJ 
https://imagej.nih.
gov/ij/   
Software, 
algorithm 
Zen 2 lite Zeiss   
Software, 
algorithm 
GraphPad 
Prism 
https://graphpad.c
om   
 456 
 457 
Animals and treatments 458 
All experimental and surgical protocols were performed following the guidelines established 459 
by the French Ministry of Agriculture (Animal Rights Division). The architecture and 460 
functioning rules of our animal house, as well as our experimental procedures have been 461 
approved by the ‘‘Direction Départementale des Services Vétérinaires’’ and the ethic 462 
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committee (ID numbers F1305521 and 2016071112151400 for animal house and research 463 
project, 464 
respectively).. Surgery and perfusions were performed under ketamine (100 mg/kg, MERIAL, 465 
Lyon, France))/xylazine (10 mg/kg, BAYER, Puteaux, France) anesthesia. C57BL/6 wild-466 
type and transgenic mice were successively used to characterize post-lesional expression of 467 
Ndst1 and HS after demyelination and to investigate the impact of conditional deletion of 468 
Ndst1 in the Olig2-positive cell population. Heterozygous Olig2-Cre+/- (from B6D2F1J/Rj 469 
genetic background) [35] and double transgenic Olig2-Cre+/-; Ndst1 
Flox/Flox
 mice [19, 35] 470 
will be referred below as control and mutant mice, respectively. Mice expressing GFP under 471 
the control of the proteolipid protein (plp, a protein largely present in myelin) promoter were 472 
used in some experiments to better observe demyelination lesions (called thereafter plpGFP 473 
mice). Animals were housed under standard conditions with enrichment and access to water 474 
and food ad libitum on a normal 12 h light/dark cycle. 475 
 476 
Human postmortem samples  477 
Postmortem unfixed frozen tissues were obtained from the UK Multiple Sclerosis Tissue 478 
Bank via a UK prospective donor scheme with full ethical approval (MREC/02/2/39). Luxol 479 
fast blue (LFB) (staining myelin; Figure7 -figure supplement 2C) and Oil Red O (staining 480 
lipids phagocytosed by macrophages) were performed to characterize and classify the lesion 481 
types [3]. Active lesions have indistinct borders on LFB and lipid-laden 482 
macrophages/microglia. Chronic active lesions have a ring of lipid-laden 483 
macrophages/microglia and a core with few immune cells. Chronic inactive lesions have a 484 
distinct border on LFB and few immune cells. Finally, shadow plaques, thought to represent 485 
remyelination, have less intense staining on LFB. This classification was done by two 486 
independent researchers for a previous publication [3]. In this study, we used active (n=7), 487 
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chronic active (n=4), chronic inactive (n=14) and remyelinated (shadow) MS plaques (n=21) 488 
from 14 blocks of brain tissue from 9 MS patients and 4 blocks of brain tissue from 4 controls 489 
with no neurological disease (Table 1)  490 
 491 
Focal demyelination in the corpus callosum and tissue processing 492 
Focal demyelination was performed by stereotactic injection of Lysolecithin (LPC) (SIGMA-493 
ALDRICH, St Louis, USA) as described previously [30, 69]. The corpus callosum from 494 
healthy or demyelinated mice, from the ipsilateral and contralateral side to the LPC-induced 495 
lesion, were dissected 7 days post injection (dpi) from 1 mm thick coronal slices in cold 496 
Hank's Balanced Salt Solution (GIBCO by life technologie, Paisley, UK) and processed for 497 
RT-qPCR analysis (Ndst1 primers : exon 6 (forward, 5′-gctggacaagatcatcaatgg-3′) and exon 7 498 
(reverse, 5′-acacagtacttctacgactatcc-3′); for Gapdh : exon1 (forward, 5’-499 
gggttcctataaatacggactgc-3’) and exon2 (reverse 5’-ctggcactgcacaagaagat-3’). Primers from 500 
EUROFINS GENOMICS, Ebersberg, GERMANY). For histological analysis, mice were 501 
anesthetized and perfused with ice-cold 4% paraformaldehyde (FISHER SCIENTIFIC, 502 
Loughborough Leics, UK) in PBS (GIBCO by life technologie, Paisley, UK). Brains were 503 
post-fixed overnight in 4% paraformaldehyde in PBS and cut on a vibratome (Leica) in 4 504 
series of coronal sections (50 µm thick) for immunofluorescence, or cryopreserved and cut 505 
with cryostat (20 µm thick) for in situ hybridization. 506 
 507 
In situ hybridization and immunohistochemistry.  508 
In situ hybridization was performed using plp/dm20 [70] and Ndst1 probes [19] as described 509 
in [71]. RNAscope Multiplex Fluorescent kit (323133; Advanced Cell Diagnostics) was used 510 
to detect Ptch1 mouse mRNA. Briefly cryosections were baked for 30 min at 60°C and 511 
dehydrated, incubated for 30min at 40°C with protease III before incubation with RNAScope 512 
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probe Ptch1 (402811-C2) for 2 hrs at 40°C.  Immunohistochemistry was performed as 513 
described in [30]. The following primary antibodies were used: rabbit anti-Olig2 (AB9610; 514 
1/1000, Millipore, USA), mouse anti-APC (CC1) (1/400; Calbiochem, USA), and rat anti-515 
PDGFRα (CBL1366; 1/250; Millipore, USA) for oligodendroglial lineage cells; anti-MBP 516 
(mouse, 1/500, Chemicon, Millipore S.A.) for myelin sheaths; mouse anti-Ki67 (556003; 517 
1/500; BD Pharmingen) for proliferating cells; rabbit anti-caspase 3 (9661; 1/200; Cell 518 
Signaling) for apoptotic cells, rabbit anti-GFAP (1/400) for astrocytes; goat anti-Iba1 (1/500, 519 
Abcam) for microglia and macrophages; rat anti-CD68 (1/400, Abcam) for activated 520 
microglia and macrophages; rabbit anti-Cox2 (1/400, Abcam) for proinflammatory M1 521 
microglia/macrophage; mouse IgM anti-N-sulfated motifs on HS chains (10E4 antibody, 522 
1/500; Seikagaku, Japan). For Olig2 and Ki67 immunofluorescence, antigen unmasking was 523 
performed by 20 min incubation in boiling citrate buffer (10mM pH6). For N-sulfated motifs 524 
labeling, floating sections from PFA perfused-brain were incubated for 2 h 30 at 37°C in 525 
buffer (100 mM Sodium Chloride, 1 mM Calcium Chloride, 50 mM Hepes 5µg, BSA pH 7)  526 
with or without Heparinase (3.3 mU from Flavobacterium heparinum, Seikagaku Kogyo Co. # 527 
100700, Japan) [34] before permeabilization. Secondary antibodies coupled to alexa 488, 555 528 
and 647 (1/500, Invitrogen Molecular Probes) were applied for 2 h 30 at RT in a humid 529 
chamber. Sections were counterstained with Hoechst 33342 (1/500, Sigma). 530 
 531 
AP-Shh recombinant protein binding test in mice 532 
Plasmids containing sequences for AP-tagged N-terminal WT or deleted Shh were produced 533 
by PCR and ligated into pWIZ vector as described in [19, 38]. Briefly, plasmids were 534 
transiently transfected into HEK cells using lipofectamine 2000 (Invitrogen). Transfection 535 
proceeded for 3 h. Culture supernatants were collected after 60 h and filtered through 0.45µm 536 
filters (Corning Incorporated, Durham, USA). Hepes 10mM pH7 was added to increase 537 
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stability. Shh concentration was then evaluated measuring AP activity in culture supernatants. 538 
Preparations from mock-transfected HEK cells were generated and used as vehicle controls. 539 
The AP-Shh binding test was performed as described in [38].  540 
Fresh frozen brain sections were post-fixed with ice-cooled methanol for 8 min. After rinsing 541 
with phosphate-buffered saline containing 4mM MgCl2 and blocking with 1% Bovine Serum 542 
Albumin (SIGMA-ALDRICH, St Louis, MO, USA) 1 h at RT, frozen adjacent sections from 543 
healthy or demyelinated C57BL/6 mice were incubated with 5nM of two AP tagged versions 544 
of Shh: AP-Shh recombinant proteins carrying the N-terminal CW sequence (AP-SHH), the 545 
main HS-binding site for Shh [38] [37], or lacking this motif (AP-SHH-CWdeleted). Sections 546 
were then washed with PBS to dissociate any low affinity interaction and endogenous 547 
phosphatases were inactivated by heating at 65°C for 2 h. AP was revealed by incubating 548 
overnight in NBT (100mg/ml) /BCIP (50mg/ml) in 100mM Tris pH 9,5 with 100mM NaCl  549 
and 50mM MgCl2. 550 
 551 
Immunohistochemistry on human post-mortem tissue 552 
Tissue was fixed in 4% paraformaldehyde in PBS for 30 min. Endogenous peroxidase and AP 553 
activity was blocked by 10 min incubation with Vector Bloxall (Vector, SP-6000 VECTOR 554 
LABORATORIES, Burlingame, USA). Slides were blocked with ready-to-use 2.5% normal 555 
horse serum from Vector secondary antibody kits for at least 20 min. Primary antibodies were 556 
incubated overnight in antibody diluent (Spring Bioscience, ADS-125) at 4°C. Primary 557 
antibodies used: mouse anti-NDST1 (1/50; Abcam, ab55296), rabbit anti-NeuN (1/500; 558 
Abcam, ab104225), rabbit anti-IBA1 (1/500; Wako chemicals, 019-19741), rabbit anti-Olig2 559 
(1/100; Sigma, HPA003254). HS staining with the mouse IgM anti-N-sulfated motifs on HS 560 
chains (10E4 antibody, Seikagaku, Japan) did not give any signal on human tissue. NDST1 561 
intensity was evaluated after a short exposition (exactly 2 min). All other stainings were fully 562 
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developed. To ensure antibody specificity, the NDST1 antibody was pre-absorbed with 563 
human NDST1 recombinant protein (Abcam, ab116875), and added to tissue sections, with no 564 
staining seen (Figure7 -figure supplement 2A-B).  565 
Secondary antibodies were incubated at RT for 1h. Staining was developed with a DAB 566 
Peroxidase (HRP) Substrate Kit (with Nickel), 3,3’-diaminobenzidine (Vector, SK-4100) and 567 
a VECTOR Blue AP Substrate Kit (Vector, SK-5300) as per manufacturer’s guidelines. 568 
Secondary antibodies used: ImmPRESS™-AP Anti-Rabbit IgG Polymer Detection Kit 569 
(Vector, MP-5401) and ImmPRESS™ HRP Anti-Mouse IgG Polymer Detection Kit, made in 570 
Horse (Vector, MP-7402). PBS washes were performed between each treatment.   571 
 572 
Microscopy and quantification 573 
For mouse tissue analysis, imaging was performed with the Apotome system (Zeiss). The 574 
demyelinated area and cell counts were evaluated using Zen software (Zeiss). 575 
Immunofluorescent or in situ hybridization positive cells were counted in every fourth section 576 
through the whole demyelinated lesion per mouse and averaged for each mouse. Cell counts 577 
are presented as the mean of at least 3 mice. For RNAscope ISH, each punctate dot signal was 578 
counted around lesion (by using ROI and analyze particule Fiji Plugins) and reported to total 579 
nuclei number. Lesion size was quantified by measuring the area of high density of nuclei in 580 
every fourth section through the whole demyelinated lesion per mouse. In this analysis, high 581 
density of nuclei was correlated with myelin loss visualized by MBP staining or by loss of 582 
fluorescence in plpGFP mice (Figure1 -figure supplement 2).  583 
For the human post-mortem tissue analysis, slides were imaged using a ZEISS Axio Scan.Z1 584 
slide scanner. One researcher marked out the lesion sites and normal appearing white matter 585 
(WM) as areas of interest, while another counted single positive (NDST1+ cells) and double 586 
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positive cells (NDST+ cells and other brain cell markers combined as above) in these areas of 587 
interest (ensuring blinding of counting).  588 
Myelin content was evaluated by double blind scoring of images taken from Plp 589 
immunostaining on brain sections (3 photos per section and 3 sections per brain). Score of 4 590 
was attributed to maximum myelination down to 0 for absence of myelin. The mean score for 591 
the control group was considered as 100%.  592 
 593 
Gene expression profile of demyelinated versus healthy mouse progenitors 594 
This protocol is fully described in Cayre et al. [30]. Briefly, OPC from eight mice induced for 595 
experimental autoimmune encephalomyelitis (EAE mice) at the peak of paralytic symptoms 596 
and from eight adult healthy mice as controls were purified using magnetic cell sorting 597 
(Miltenyi Biotec). This experiment was replicated in an independent similar experiment. 598 
cDNAs were prepared and used (250 ng) as template for Cy3 and Cy5, combined and 599 
hybridized to Agilent Whole Mouse Genome Oligo Microarrays 4Å~44K. Agilent Feature 600 
Extraction Software (FES) determines feature intensities and ratios (including background 601 
subtraction and normalization), rejects outliers and calculates statistical confidences (P-602 
values). We obtained a gene list with all normalized Cy5/Cy3 log10 ratios, Cy5/Cy3 fold 603 
changes, sequence description and P-values. Microarray data are available at GEO with 604 
accession number GSE47486. 605 
 606 
Statistical analysis 607 
All the presented values in mice are means ± S.E.M unless otherwise stated. Data were 608 
statistically processed with the non-parametric Mann-Whitney test (independent two group 609 
comparisons). P<0.05 was considered significant and p<0.01 highly significant. All 610 
measurements and subsequent evaluations were performed blind to the experimental group to 611 
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which the animals belonged. For the human post-mortem tissue analysis, a d'Agostino and 612 
Pearson omnibus normality test was used to test whether the data fits a normal distribution 613 
and a parametric test were done only if all compared data sets passed the normality test. The 614 
NDST1+ cells in control versus multiple sclerosis WM was compared using a two-tailed 615 
Mann Whitney U test. Multiple sclerosis lesions and their surrounding WM were compared 616 
using a paired two-tailed t test. The absolute numbers of NDST1+ cells and double positive 617 
NDST1+ OLIG2+ cells in individual lesions/normal appearing WM were compared by 618 
Kruskal-Wallis test. As MS tissue blocks contained more than one lesion, and we had several 619 
blocks from the same patients, we gave each patient an overall remyelination ability score 620 
corresponding to how many lesions in the blocks from that patient were remyelinated, or 621 
likely to remyelinate if the patient had survived. Remyelinated lesions received an arbitrary 3 622 
points, active lesions 2 points, chronic active lesions 1 point and chronic inactive lesions 0 623 
points. This was divided by the number of lesions counted for each patient, to allow 624 
comparisons.  625 
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 789 
Figure 1. Ndst1 up-regulation upon LPC-induced demyelination of the corpus callosum. 790 
(A) Scheme showing the site of LPC injection (red point) in the adult corpus callosum and the 791 
location of picture shown in C (red rectangle). (B) Ndst1 expression levels (RT-qPCR) in the 792 
corpus callosum of healthy or demyelinated mice, contralateral (contra) and ipsilateral (ipsi) 793 
to the lesion site showing the Ndst1 up-regulation in the ipsilateral side. Tissues from 5 mice 794 
were pooled in each condition. Error bars represent S.E.M. *p<0.05, non-parametric ANOVA 795 
followed by Kruskal-Wallis test (independent two group comparisons). (C-H) Ndst1 in situ 796 
hybridization performed at 5 (C-F, n=4), 8 (G, n=4) and 14 (H, n=4) dpi illustrating the Ndst1 797 
expression pattern at different time points of demyelination (C-F) and remyelination (G-H). 798 
(D-E) Enlarged views of the CC in C corresponding to contralateral side (D) and positive 799 
cells at the margin of the demyelinated area at the site of LPC injection (E). CC, corpus 800 
callosum; Cx, cortex; SVZ, sub-ventricular zone; V, ventricle (structures are delineated by 801 
brown dotted lines, lesion with white dotted lines). Scale bars: 50 µm in F, G and H; 20 µm in 802 
D, F, H; 10 µm in D and E Asterisk in G indicates the site of injection since the demyelinated 803 
lesion is no longer visible at 14 dpi. 804 
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 805 
Figure 1-figure supplement 1. Ndst1 is up-regulated by the Olig2+ cell population in 806 
close proximity to inflammation sites in corpus callosum, in the experimental 807 
autoimmune encephalomyelitis mouse model of demyelination. Ndst1 is not expressed in 808 
control brain (A) (n=2) while it is up-regulated by Olig2+ cells after experimental 809 
autoimmune encephalomyelitis induction (B)(n=3) in close proximity to lesions in the corpus 810 
callosum (C). Enlarged views correspond to boxed region. CC, corpus callosum. Scale bars: 811 
50 µm in A-B; 20 µm in C. 812 
 813 
Figure 1 Supplement 2. PlpGFP mice (n=3) were used to detect demyelinated lesions (A, B, 814 
D, E). Demyelination was clearly visible in the corpus callosum around the injection site by 815 
the lack of GFP fluorescence (B, E). Hoechst staining shows a high cell density (C, F) 816 
correlating with the loss of myelin (A, D). CC, corpus callosum, Cx, cortex, V, ventricle, St, 817 
Striatum. Scale bars: 100 µm. 818 
 819 
Figure 2. N-sulfate-enriched microenvironment forms a belt around the demyelinated 820 
lesion. HS (10E4) labeling on the contra- (A) and ipsi- (B-C) lateral side to the lesion 821 
illustrates the generation of a N-sulfated microenvironment surrounding the lesion (delimited 822 
by white dashed lines) at 5 dpi (n=3). No immunoreactivity was found after Heparinase I 823 
treatment (D) thus validating the 10E4 antibody specificity. Scale bars: 20 µm in A, B, D; 824 
10 µm in C. CC, corpus callosum; V, ventricle.  825 
 826 
Figure 3. Ndst1 expressing cells around the lesion belong to the oligodendroglial lineage. 827 
(A-B) Ndst1 in situ hybridization successively combined with Olig2 immunostaining (A) or 828 
Plp in situ hybridization (B) labeling, two OLG markers, illustrating Ndst1 up-regulation in 829 
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oligodendroglia lineage cells surrounding the lesion site at 5 dpi (n=3). (C-D) Representative 830 
images of Ndst1/PDGFRα (C) and Ndst1/CC1 (D) co-labeling illustrating that both OPC (C) 831 
and mature OLG (D) up-regulate Ndst1 after demyelination at 5 dpi (n=4). Inserts in (A-D) 832 
illustrate boxed regions at high magnification. Scale bars: 20 µm. 833 
 834 
 835 
Figure 4. Deletion of Ndst1 in Olig2+ cells affects lesion size and OPC mobilization after 836 
LPC-induced demyelination of the corpus callosum.  837 
(A-B) Representative images of the lesion site (delineated by white dashed lines) in the 838 
corpus callosum of control (A) and mutant (B) mice at 8 dpi illustrating the enlargement of 839 
the lesion size in mutant mice compared to control mice. (C) Quantitative analysis of the 840 
lesion size at 4, 8 and 14 dpi (n=8,9,4 control and n=9,12,6 mutant mice respectively). (D-E) 841 
Oligodendroglia labeled by Olig2 staining within the demyelinated area at 8 dpi (E) compared 842 
to control mice (D). (F) Olig2 mean cell density in healthy (CTL) or demyelinated control and 843 
mutant mice at 4, 8, 14 dpi. (G-H) Mature OLG co-labeled by Olig2/CC1 within the 844 
demyelinated lesion at 8 dpi in control (G) and mutant (H) mice. (I) Quantification of mean 845 
cell density of Olig2+/CC1+ cells within the demyelination lesion in healthy (CTL) or 846 
demyelinated control and mutant mice at 4, 8, 14 dpi. (J-K) Ki67+ immunolabeling shows the 847 
proliferation status of cells within the lesion 8dpi in control (J) and mutant (K) mouse. (L) 848 
Graph represents the cell proliferation (Ki67+ cells) in mutant relative to control mice at 4 849 
and 8 dpi (n=9,12 control and n=8,16 mutant mice respectively). (M-N) Co-immunolabelling 850 
of Olig2 and Ki67 showing OPC proliferation in control (M) and mutant (N) mouse 8dpi.  (I) 851 
Quantification of proliferating OPC (Ki67+/olig2+ cells) in lesion sites at 4 and 8 dpi (n=6,11 852 
control and n=7,13 mutant mice respectively). Error bars represent S.E.M. *p<0.05, 853 
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***p<0.001, non-parametric Mann-Whitney test (independent two group comparisons). Scale 854 
bars: 50 µm in A, B, D, E and 10 µm in, G, H, J, K, M and N. 855 
Figure 4- figure supplement 1. Ndst1 inactivation in oligodendrocyte lineage cells in 856 
Olig2-Cre+/-; Ndst1 
Flox/Flox
 mice. (A-B) Representative images of the lesion site (delineated 857 
by white dashed lines) in the corpus callosum of control (A) (n=2) and mutant (B) (n=2) mice 858 
at 8 dpi illustrating the enlargement of the lesion size in mutant mice compared to control 859 
mice. Olig2 (in red) is used to label oligodendrocyte lineage cells. In situ hybridization 860 
revealed a marked reduction in Ndst1 expression surrounding the lesion site in mice with 861 
conditional inactivation in the oligodendroglial lineage cells (B, D, F) compared to control 862 
mice (A, C, E). C and D are high magnifications of the squares in A and B respectively. E and 863 
F are high magnifications of the squares in C and D respectively. Representative images of 864 
10E4 immunostaining at the lesion site (delineated by white dashed lines. 8dpi) in the corpus 865 
callosum of control (G) and mutant (H) mice showing a strong reduction of heparan sulfate 866 
labeling in absence of Ndst1 in oligodendrocytes. CC, corpus callosum, V, ventricle, St, 867 
Striatum. Scale bars: 100 µm in A-; 20 µm in C-D. 30 µm in G-H 868 
 869 
  870 
Figure 4 –figure supplement 2. Myelin content and glial density in adult unlesioned 871 
Olig2-Cre+/-; Ndst1 
Flox/Flox
 mice. (A-B) Representative images of the myelin content in the 872 
corpus callosum of control (A) and Olig2-Cre; Ndst1 
Flox/Flox
 (B) mice. (C) Quantitative 873 
analysis of the myelin content by double blind scoring of PLP staining in control (n=3) and 874 
mutant mice (n=3). Results are expressed in percentage of the control. (D-E) Astrocyte 875 
labeling by GFAP immunofluorescence in the corpus callosum of control (D) (n=2) and 876 
mutant (n=3) mouse brain (E). (G-H, J-K) Phenotype of oligodendroglia in the corpus 877 
callosum of control (G, J) (n=5) and mutant (H, K) (n=5) mice by triple immunostaining for 878 
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Olig2/PDGFRα/CC1. (F, I) Quantification of mean cell density of astrocytes (GFAP+ cells) 879 
(n=2 and 3) (F) and oligodendroglia (Olig2+ cells) (I) in the corpus callosum of control and 880 
mutant mice (n=5 in each group). (L) Quantitative analysis of the percentage of Olig2+/CC1+ 881 
and Olig2+/PDGFRα+ in the corpus callosum of control and mutant mice (n=?). No 882 
significant difference was observed between the 2 groups using non-parametric Mann-883 
Whitney test (independent two group comparisons).   Error bars represent S.E.M. Scale bars: 884 
10 µm. 885 
 886 
Figure 5. Effect of Ndst1 deletion on microglia/macrophage activation.  887 
(A-B) CD68+/Ki67+ co-immunolabeling shows the proliferation status of activated 888 
microglia/macrophages. (C) Quantification of proliferating microglia/macrophages 889 
(Ki67+/CD68+ cells) in lesion sites at 4 and 8 dpi (n=3,7 control and n=3,7 mutant mice 890 
respectively). Iba1 (D-E) and CD68 immunolabeling (F-G) shows the increase in rhomboid-891 
polarized microglia/macrophages in the demyelinated area of mutant mice at 8 dpi. (H) 892 
Quantification of the ratio of rhomboid/branched CD68+ cells in lesion sites at 4 and 8 dpi 893 
(n=3,4 control and n=3,6 mutant mice respectively) showing a switch of the 894 
microglia/macrophage polarization in favor of the rhomboid phenotype in mutant mice at 895 
8 dpi.  (I-J) Cox2 immunolabeling shows an increase in this M1 phenotype marker at 8dpi in 896 
mutant mice. (K) Quantification of Cox2+ cells in lesion sites at 8dpi (n=4 control and n=5 897 
mutant mice).  Error bars represent S.E.M. *p≤0.05, non-parametric Mann-Whitney test 898 
(independent two group comparisons). Scale bars: 50 µm in I-J and 10 µm in A-B, D-E, F-G. 899 
 900 
 901 
Figure 6. AP-tagged Shh protein binds to HS concentrated around LPC-induced lesions 902 
in the corpus callosum. Representative images of adjacent serial coronal sections derived 903 
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from control mice 4 days after LPC injection and incubated with the fusion proteins AP-Shh-904 
WT (A-B’) or AP-Shh-CW in which the CW sequence responsible for HS binding is absent 905 
(C-D) (n=4). The lesion site is delineated by dashed lines. Staining using B-gal is clearly 906 
visible around the lesion after AP-Shh incubation (B-B’), while no staining is observed when 907 
the AP-Shh-CW deleted protein is used (D). These data show that Shh is concentrated around 908 
the lesion and that this distribution depends on the integrity of the HS binding motif. (E) 909 
Quantification of Ptch1 expression at 8dpi in control and mutant mice reported in number of 910 
dots per cell (n=4 control and n=5 mutant mice). (F-G) Illustration of Ptch1 expression in 911 
peri-lesional areas in control (F) and mutant (G) mice after labeling as detected by RNAscope 912 
technology. CC, corpus callosum; Cx, cortex. Scale bars: 100µm in A-D.  10 µm in F and G.   913 
 914 
Figure 7. NDST1 is highly expressed in MS tissue and NDST1+OLIG2+ cell density 915 
negatively correlates with lesion size. (A-B) Representative images of NDST1 staining in 916 
control (A) and MS (B) WM. (C) Quantification of NDST1 labeling shows a significant over-917 
expression of NDST1 in MS lesions (n=9) compared to control tissue (n=4) (Kruskal-Wallis 918 
test, H=13.09, n=4,9,9, p<0.01, means plus standard deviation). The colors represent paired 919 
samples from the same patients. (D-G) Representative images of immunostaining against 920 
NDST1 successively co-labelled with OLIG2+ for oligodendroglia (D), GFAP+ for astrocytes 921 
(E), NEUN+ for neurons (F), and IBA1+ for microglia/macrophages (G). (H) Quantification 922 
of the proportions of different NDST1+ cell types in normal appearing WM and various MS 923 
lesions shows that NDST1 expressing cells are mainly oligodendroglia. (I) The proportion of 924 
OLIG2+ cells which is NDST1+ is significantly increased in active lesions compared to 925 
control (Kruskal-Wallis test, H=13.92, n=7,21,4,14,14 p<0.05). Overall, the majority of 926 
OLIG2+ cells are NDST1+ in MS lesions and NAWM while this is not true in control brain 927 
tissue. (J) The number of oligodendroglia expressing NDST1 is inversely correlated to lesion 928 
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size. (K) NDST1+ cell numbers positively correlate with the remyelination score assigned to 929 
each patient, summing all lesions within blocks from the same MS patients (see methods). 930 
NAWM, normal appearing white matter; RM, remyelinated lesion; A, active lesion; CA, 931 
chronic active lesion; CI, chronic inactive lesion. Scale bars represent 50 µm (A-B) or 10 µm 932 
(D-G). 933 
 934 
Figure 7-figure supplement1. Comparisons of Ndst1 expression levels in control and MS 935 
brain tissue from all nuclei (A), or just oligodendroglia (B) showing a tendency to 936 
increased levels in MS samples. Data extracted from snRNA seq [37]. 937 
 938 
Figure 7-figure supplement2. NDST1 staining is specific and no lesion belt effect is 939 
observed in human brain. (A) Staining with NDST1 antibody in MS WM (B) There is no 940 
staining of MS WM with NDST1 antibody in in the presence of human recombinant NDST1. 941 
(C) LFB stain of MS tissue with the lesion delineated in red. (D) Representative NDST1+ 942 
staining in lesion (delineated with red line) shows uniform NDST1+ cell distribution. Scale 943 
bars: 100 µm. 944 
 945 
 946 
  947 
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Patient Sex 
Age 
(years) 
MS 
type 
Disease 
duration 
(years) 
Time to 
post 
mortem 
(h) 
Number 
of lesions 
Active 
Chronic 
active 
Chronic 
inactive 
Remyeli-
nating 
MS 
MS100 M 46 SP 8 7 6 0 0 4 2 
MS121 F 49 SP 14 24 2 1 0 1 0 
MS122 M 44 SP 10 16 2 1 1 0 0 
MS136 M 40 SP 9 10 9 1 0 3 5 
MS154 F 34 SP 21 12 4 2 0 1 1 
MS176 M 37 PP 27 12 7 0 0 2 5 
MS187 F 57 SP 27 13 4 0 0 0 4 
MS207 F 46 SP 25 10 8 0 3 3 2 
MS230 F 42 SP 19 31 4 2 0 0 2 
Control 
CO14 M 64 - - 26 - - - - - 
CO25 M 35 - - 22 - - - - - 
CO28 F 60 - - 13 - - - - - 
CO39 M 82 - - 21 - - - - - 
Total  46 7 4 14 21 
Table 1: Classification and characteristic of human post-mortem samples. 948 
 949 













